BioNTech SE Hosts Innovation Series R&D Day

TL;DR

BioNTech held its R&D Day on Nov 11, 2025, showcasing its innovation pipeline.

AI Summary

On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, presenting an overview of its research and development pipeline. The company, headquartered in Mainz, Germany, provided updates on its advancements in various therapeutic areas.

Why It Matters

This event provides investors and the public with insights into BioNTech's future product development and strategic direction in the biotechnology sector.

Risk Assessment

Risk Level: low — This filing is an informational update on an R&D event and does not contain material financial changes or new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• November 11, 2025 (date) — Date of R&D Day
• Mainz, Germany (location) — Company Headquarters

FAQ

From the Filing

0001776985-25-000067.txt : 20251112 0001776985-25-000067.hdr.sgml : 20251112 20251112074533 ACCESSION NUMBER: 0001776985-25-000067 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 177 CONFORMED PERIOD OF REPORT: 20251112 FILED AS OF DATE: 20251112 DATE AS OF CHANGE: 20251112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251468930 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-krddaypresentation12.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 11, 2025, BioNTech SE (the “Company”) hosted an edition of the Company’s Innovation Series R&D Day, providing an overview of the Company’s strategy and clinical progress across its pipeline. The presentation is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Ramon Zapata-Gomez By: /s/ Dr. Sierk Poetting Name: Ramon Zapata-Gomez Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: November 12, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Presentation EX-99.1 2 ex991bntxinnovationserie.htm EX-99.1 ex991bntxinnovationserie Innovation Series: R&D Day 2025 November 11th, 2025 Exhibit 99.1 Introductory Remarks Douglas Maffei, PhD, Vice President, Strategy and Investor Relations 1 3 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and fu